Human Subjects Clinical Core Component 2

人类受试者临床核心部分 2

基本信息

项目摘要

PROJECT SUMMARY The Clinical Core is an ideally-situated brain injury research hub, with state-of-the-science neuropsychological, electrophysiological and neuroimaging instrumentation to measure brain injury function and novel neurostimulation technologies for studies of brain injury recovery and repair. The Clinical Core is a collaborative, interdisciplinary environment providing expert guidance in research design and methods, critical support for patient recruitment, data collection and management to ensure reliability and reproducibility of results, and assistance with regulatory compliance using Good Clinical Practices. Collectively, this platform has unleashed the brain injury research potential at UNM to improve the outcomes of individuals with brain injuries. The Clinical Core has succeeded in propelling our young, promising investigators to independent research funding status and is now established as a national leader in research applying innovative neuromodulation approaches to therapeutically target and alter specific neural circuitries in individuals with neurological conditions. Overall, the goal of the Core in Phase II is to build on our Phase I accomplishments and continue our progress towards becoming a self-sustaining research enterprise that is independent of IDeA funding. We will continue to provide the resources and expertise to support innovative research that will accelerate a new cohort of Project Leads to independent funding and expand our mass of new and established clinical investigators as Core users on a fee for service basis. The Core will continue to invest in new instrumentation, advance our recruiting approaches and ensure tracking and reporting to Human Subjects System (HSS) and Clinical Trials.gov. The Clinical Core will continue to foster multidisciplinary collaboration between clinical and preclinical investigators within UNM and reach out to state and regional institutions to develop new partnerships and training collaborations as we seek to be a leading resource center for brain research. Through these efforts we will search for new interventions for brain and behavioral illnesses that will lead to improved outcomes for individuals with brain injury and their families.
项目摘要 临床中心是一个理想的脑损伤研究中心,拥有最先进的神经心理学, 电生理和神经成像仪器来测量脑损伤功能, 神经刺激技术用于脑损伤恢复和修复的研究。临床核心是一个 协作,跨学科的环境提供专家指导的研究设计和方法,关键 支持患者招募、数据收集和管理,以确保 结果,并使用良好的临床实践协助遵守法规。总的来说,这个平台 释放了UNM的脑损伤研究潜力,以改善脑损伤患者的预后。 临床核心已经成功地推动我们年轻的,有前途的研究人员进行独立的研究 基金状况,现在被确立为应用创新神经调节研究的国家领导者 治疗性靶向和改变神经系统疾病个体的特定神经回路的方法 条件总的来说,第二阶段核心的目标是在第一阶段成就的基础上继续发展, 我们朝着成为一个独立于IDEA资金的自我维持的研究企业的方向取得了进展。我们 将继续提供资源和专业知识,以支持创新研究,这将加速一个新的 项目的队列导致独立的资金和扩大我们的新的和建立的临床质量 研究者作为核心用户,按服务收费。核心将继续投资于新的仪器, 推进我们的招募方法,并确保跟踪和向人类受试者系统(HSS)报告, 临床核心将继续促进临床和实验室之间的多学科合作。 UNM内的临床前研究人员,并与州和地区机构联系,以开发新的 伙伴关系和培训合作,因为我们寻求成为大脑研究的领先资源中心。 通过这些努力,我们将寻找大脑和行为疾病的新干预措施, 改善脑损伤患者及其家人的预后。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessica D Richardson其他文献

Jessica D Richardson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jessica D Richardson', 18)}}的其他基金

Optimizing Targeted Interventions for Aphasia
优化失语症的针对性干预措施
  • 批准号:
    10400003
  • 财政年份:
    2021
  • 资助金额:
    $ 24.46万
  • 项目类别:
Optimizing Targeted Interventions for Aphasia
优化失语症的针对性干预措施
  • 批准号:
    10614986
  • 财政年份:
    2021
  • 资助金额:
    $ 24.46万
  • 项目类别:
Optimizing Targeted Interventions for Primary Progressive Aphasia
优化原发性进行性失语症的针对性干预措施
  • 批准号:
    10712767
  • 财政年份:
    2021
  • 资助金额:
    $ 24.46万
  • 项目类别:
Enhance Treatment Outcomes in Persons with Aphasia
提高失语症患者的治疗效果
  • 批准号:
    10158650
  • 财政年份:
  • 资助金额:
    $ 24.46万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 24.46万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了